The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of isocitrate dehydorgenase-1 (IDH-1) mutations with elevated oncometabolite 2-hydroxyglutarate (2HG) in advanced colorectal cancer.
 
Nazanin Fallah-Rad
No Relationships to Disclose
 
Philippe L. Bedard
Consulting or Advisory Role - Genentech/Roche (Inst); Pfizer (Inst); Sanofi (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Oncothyreon (Inst); PTC Therapeutics (Inst); Sanofi (Inst); SERVIER (Inst); SignalChem (Inst)
 
Lillian L. Siu
Leadership - Agios (I)
Stock and Other Ownership Interests - Agios (I); Entremed (I)
Consulting or Advisory Role - Boehringer Ingelheim; Daiichi Sankyo; Merck; Novartis (Inst); Oncoethix
Research Funding - Abraxis BioScience; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Celgene; Genentech/Roche; GlaxoSmithKline; Karyopharm Therapeutics; MedImmune; Merck; Novartis; Pfizer; Regeneron
 
Suzanne Kamel-Reid
No Relationships to Disclose
 
Helen Chow
No Relationships to Disclose
 
Zhang Weijiang
No Relationships to Disclose
 
Raymond Jang
No Relationships to Disclose
 
Monika K. Krzyzanowska
Honoraria - Bayer; Eisai
Research Funding - AstraZeneca (Inst); Eisai (Inst); Exelixis (Inst); Novartis (Inst)
Other Relationship - Bayer/Onyx
 
Albiruni R. A. Razak
No Relationships to Disclose
 
Eric Xueyu Chen
No Relationships to Disclose